AIM VACCINE (06660) announced on August 3 that its independently developed serum-free iterative rabies vaccine has successfully completed on-site inspection following a marketing registration application submission to the National Medical Products Administration.

Earlier this year, the company's subsidiary received a supplementary data notice from the Center for Drug Evaluation, a standard step in the vaccine review process. AIM VACCINE has since compiled additional information per review comments and submitted the supplemental materials, marking significant progress in the registration process for its serum-free iterative rabies vaccine.

Industry experts have previously noted that serum-free technology represents a valuable exploration direction in vaccine production, reflecting the industry's ongoing efforts to pursue higher standards and continuous innovation. This advancement opens new possibilities for future vaccine manufacturing. As the world's second-largest rabies vaccine producer, AIM VACCINE is gradually turning this innovative technology into reality.

According to results from a completed Phase III clinical trial that was unblinded, the serum-free iterative rabies vaccine developed by AIM VACCINE demonstrates good safety, immunogenicity, and immune persistence, fully meeting the preset evaluation criteria for the clinical study. The company's subsidiary had previously obtained the corresponding production license for this serum-free rabies vaccine.

Once the serum-free rabies vaccine is launched, AIM VACCINE will further solidify its global leadership in the rabies vaccine field. At a recent industry forum, experts pointed out that rabies vaccines have undergone gradual iterative upgrades since their inception, with the serum-free version being the latest generation. They recommended increased market attention and understanding of this new product.

Additionally, experts noted that international studies show the incidence of adverse reactions at the injection site for serum-free rabies vaccines is significantly lower than for Vero cell rabies vaccines. The upcoming serum-free rabies vaccine from AIM VACCINE essentially removes nearly all high-risk components from the vaccine, making it potentially the optimal solution for cell-cultured rabies vaccines.

According to statistics from CIConsulting, driven by product iteration and increased rabies vaccine普及率, China's rabies vaccine market is expected to reach 148 billion yuan by 2030. The approval and commercial launch of AIM VACCINE's serum-free iterative rabies vaccine could lead to a substantial increase in the company's performance.